{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-039020","form_type":"8-K","ticker":"GRCE","cik":"0001444192","company_name":"Grace Therapeutics, Inc.","filed_at":"2025-10-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.426406+00:00","generated_at":"2026-05-17T02:29:11.487212+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Grace Therapeutics secures $4.0M from warrant exercise; GTx-104 PDUFA date set for April 23, 2026","bullets":["Secured $4.0M via exercise of 1,345,464 common warrants at $3.003/share from September 2023 private placement.","Remaining 1,190,927 warrants from the same placement expired after FDA accepted GTx-104 NDA for review.","FDA set PDUFA target date of April 23, 2026 for GTx-104 NDA for aneurysmal subarachnoid hemorrhage (aSAH).","GTx-104 is a novel injectable nimodipine formulation for I.V. infusion in aSAH patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-039020","json":"https://secwatch.observer/filing/0001140361-25-039020.json","markdown":"https://secwatch.observer/filing/0001140361-25-039020.md","text":"https://secwatch.observer/filing/0001140361-25-039020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1444192/000114036125039020/0001140361-25-039020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1444192/000114036125039020/ef20057547_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:29:11.487212+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}